Vident Investment Advisory, LLC Adaptimmune Therapeutics PLC Transaction History

Vident Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$4.0 - $9.2 $532,960 - $1.23 Million	-133,240 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$7.66 - $10.78 $55,833 - $78,575	-7,289 Reduced 5.19%	133,240 $1.06 Million
Q2 2020 Jul 17, 2020	BUY	$2.58 - $12.1 $362,564 - $1.7 Million	140,529 New	140,529 $1.41 Million
Q2 2019 Aug 12, 2019	SELL	$3.23 - $5.41 $934,568 - $1.57 Million	-289,340 Closed	0 $0
Q1 2019 May 08, 2019	SELL	$3.63 - $6.06 $34,521 - $57,630	-9,510 Reduced 3.18%	289,340 $1.24 Million
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $400,812 - $1.51 Million	106,599 Added 55.45%	298,850 $1.72 Million
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $111,231 - $182,382	-13,450 Reduced 6.54%	192,251 $2.61 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $267,252 - $352,403	-25,648 Reduced 11.09%	205,701 $2.44 Million
Q1 2018 May 14, 2018	BUY	$7.1 - $11.56 $439,795 - $716,061	61,943 Added 36.56%	231,349 $2.87 Million
Q4 2017 Feb 15, 2018	SELL	$6.68 - $8.74 $546,016 - $714,398	-81,739 Reduced 32.55%	169,406 $1.13 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $1.24 Million - $2.24 Million	251,145	251,145 $2.06 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $88.2M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.